The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY

Key arguments for CSA skeptics: - definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is - we still struggle to prevent RA - it’s easy to go down a therapeutic slippery slope, and hard to track back - labels are hard to remove #EULAR2023 @RheumNow https://t.co/4adop3IR8g

Presenting work to improve referrals from primary care, reducing delays in diagnosis in rheumatic conditions. Sharing the set up of Rheumatology Academy and Collaborative Network (RheumACaN) and the impact it is making @RBNHSFT @NASSexercise @RheumatologyUK @RheumNow #EULAR2023 https://t.co/v0BBRiFtEy

Check out RheumNow's #EULAR23 coverage! https://t.co/rGBWF0lx4g https://t.co/6SEon6poi4

• https://bit.ly/3OVhlu2

RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

RheumNow Eular 2023 Daily Recap Series https://t.co/ScW9jWvzl9

• https://twitter.com/i/broadcasts/1lPJqBVQMXYxb

So Annette van der Helm-van Mil makes some clear arguments about why CSA is real. But Filip Van den Bosch gives his disclosure: the clinical rheumatologist’s inherent skepticism of ‘early disease’ #EULAR2023 @RheumNow https://t.co/GbaBhQE5AB

ILD in RA and PsA @AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD. ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis. https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N

• https://bit.ly/3oIxxnR

Using app for self-management in clinical care. There is a need to have continued engagement both patients and clinicians, constantly evolve the product, adapt to the changing needs of patients eg.pre and post pandemic, #WIIFM? @AurelieRheumo @ProfYelizPrior #EULAR2023 @RheumNow https://t.co/5RKog9EMsV

Metabolic Burden in the Early Stages of PsA Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy. https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH

• https://bit.ly/3JcZawv